Literature DB >> 33713831

Two Hours of In Vivo Lung Perfusion Improves Lung Function in Sepsis-Induced Acute Respiratory Distress Syndrome.

Matthew R Byler1, Nathan S Haywood1, Dustin T Money1, Aimee Zhang1, Jared P Beller1, Eric J Charles1, William Z Chancellor1, Huy Q Ta1, Mark H Stoler2, J Hunter Mehaffey1, Victor E Laubach1, Irving L Kron1, Mark E Roeser3.   

Abstract

Sepsis is the leading cause of acute respiratory distress syndrome (ARDS) in adults and carries a high mortality. Utilizing a previously validated porcine model of sepsis-induced ARDS, we sought to refine our novel therapeutic technique of in vivo lung perfusion (IVLP). We hypothesized that 2 hours of IVLP would provide non-inferior lung rehabilitation compared to 4 hours of treatment. Adult swine (n = 8) received lipopolysaccharide to develop ARDS and were placed on central venoarterial extracorporeal membrane oxygenation. Animals were randomized to 2 vs 4 hours of IVLP. The left pulmonary vessels were cannulated to IVLP using antegrade Steen solution. After IVLP treatment, the left lung was decannulated and reperfused for 4 hours. Total lung compliance and pulmonary venous gases from the right lung (control) and left lung (treatment) were sampled hourly. Biochemical analysis of tissue and bronchioalveolar lavage was performed along with tissue histologic assessment. Throughout IVLP and reperfusion, treated left lung PaO2/FiO2 ratio was significantly higher than the right lung control in the 2-hour group (332.2 ± 58.9 vs 264.4 ± 46.5, P = 0.01). In the 4-hour group, there was no difference between treatment and control lung PaO2/FiO2 ratio (258.5 ± 72.4 vs 253.2 ± 90.3, P = 0.58). Wet-to-dry weight ratios demonstrated reduced edema in the treated left lungs of the 2-hour group (6.23 ± 0.73 vs 7.28 ± 0.61, P = 0.03). Total lung compliance was also significantly improved in the 2-hour group. Two hours of IVLP demonstrated superior lung function in this preclinical model of sepsis-induced ARDS. Clinical translation of IVLP may shorten duration of mechanical support and improve outcomes.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute lung injury; In vivo lung perfusion; Lung rehabilitation

Mesh:

Substances:

Year:  2021        PMID: 33713831      PMCID: PMC8433279          DOI: 10.1053/j.semtcvs.2021.02.034

Source DB:  PubMed          Journal:  Semin Thorac Cardiovasc Surg        ISSN: 1043-0679


  36 in total

1.  Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials.

Authors:  Carolyn S Calfee; Kevin Delucchi; Polly E Parsons; B Taylor Thompson; Lorraine B Ware; Michael A Matthay
Journal:  Lancet Respir Med       Date:  2014-05-19       Impact factor: 30.700

Review 2.  Acute Respiratory Distress Syndrome.

Authors:  B Taylor Thompson; Rachel C Chambers; Kathleen D Liu
Journal:  N Engl J Med       Date:  2017-08-10       Impact factor: 91.245

3.  Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome.

Authors:  Alain Combes; David Hajage; Gilles Capellier; Alexandre Demoule; Sylvain Lavoué; Christophe Guervilly; Daniel Da Silva; Lara Zafrani; Patrice Tirot; Benoit Veber; Eric Maury; Bruno Levy; Yves Cohen; Christian Richard; Pierre Kalfon; Lila Bouadma; Hossein Mehdaoui; Gaëtan Beduneau; Guillaume Lebreton; Laurent Brochard; Niall D Ferguson; Eddy Fan; Arthur S Slutsky; Daniel Brodie; Alain Mercat
Journal:  N Engl J Med       Date:  2018-05-24       Impact factor: 91.245

4.  Cytoprotective and Antioxidant Effects of Steen Solution on Human Lung Spheroids and Human Endothelial Cells.

Authors:  F Pagano; C Nocella; S Sciarretta; L Fianchini; C Siciliano; G Mangino; M Ibrahim; E De Falco; R Carnevale; I Chimenti; G Frati
Journal:  Am J Transplant       Date:  2017-04-26       Impact factor: 8.086

5.  Tocilizumab in patients with severe COVID-19: a retrospective cohort study.

Authors:  Giovanni Guaraldi; Marianna Meschiari; Alessandro Cozzi-Lepri; Jovana Milic; Roberto Tonelli; Marianna Menozzi; Erica Franceschini; Gianluca Cuomo; Gabriella Orlando; Vanni Borghi; Antonella Santoro; Margherita Di Gaetano; Cinzia Puzzolante; Federica Carli; Andrea Bedini; Luca Corradi; Riccardo Fantini; Ivana Castaniere; Luca Tabbì; Massimo Girardis; Sara Tedeschi; Maddalena Giannella; Michele Bartoletti; Renato Pascale; Giovanni Dolci; Lucio Brugioni; Antonello Pietrangelo; Andrea Cossarizza; Federico Pea; Enrico Clini; Carlo Salvarani; Marco Massari; Pier Luigi Viale; Cristina Mussini
Journal:  Lancet Rheumatol       Date:  2020-06-24

6.  Ex Vivo Lung Perfusion Rehabilitates Sepsis-Induced Lung Injury.

Authors:  J Hunter Mehaffey; Eric J Charles; Ashish K Sharma; Morgan Salmon; Dustin Money; Sarah Schubert; Mark H Stoler; Curtis G Tribble; Victor E Laubach; Mark E Roeser; Irving L Kron
Journal:  Ann Thorac Surg       Date:  2017-04-21       Impact factor: 4.330

7.  Technique for prolonged normothermic ex vivo lung perfusion.

Authors:  Marcelo Cypel; Jonathan C Yeung; Shin Hirayama; Matthew Rubacha; Stefan Fischer; Masaki Anraku; Masaaki Sato; Stephen Harwood; Andrew Pierre; Thomas K Waddell; Marc de Perrot; Mingyao Liu; Shaf Keshavjee
Journal:  J Heart Lung Transplant       Date:  2008-12       Impact factor: 10.247

8.  Modified in vivo lung perfusion allows for prolonged perfusion without acute lung injury.

Authors:  Pedro Reck dos Santos; Ilker Iskender; Tiago Machuca; David Hwang; Marc dePerrot; Mingyao Liu; Shaf Keshavjee; Thomas K Waddell; Marcelo Cypel
Journal:  J Thorac Cardiovasc Surg       Date:  2013-11-27       Impact factor: 5.209

9.  The ratio of Th17/Treg cells as a risk indicator in early acute respiratory distress syndrome.

Authors:  Zhi-xin Yu; Mu-sen Ji; Jun Yan; Yan Cai; Jing Liu; Hong-feng Yang; Yong Li; Zhao-chen Jin; Jin-Xu Zheng
Journal:  Crit Care       Date:  2015-03-11       Impact factor: 9.097

10.  Ex vivo lung perfusion with perfusate purification for human donor lungs following prolonged cold storage.

Authors:  Dong Wei; Fei Gao; Zhenkun Yang; Wei Wang; Yinglun Chen; Yan Lu; Jingyu Chen
Journal:  Ann Transl Med       Date:  2020-02
View more
  1 in total

1.  Steen solution protects pulmonary microvascular endothelial cells and preserves endothelial barrier after lipopolysaccharide-induced injury.

Authors:  Huy Q Ta; Nicholas R Teman; Irving L Kron; Mark E Roeser; Victor E Laubach
Journal:  J Thorac Cardiovasc Surg       Date:  2022-04-18       Impact factor: 6.439

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.